Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas
Status:
Recruiting
Trial end date:
2021-12-15
Target enrollment:
Participant gender:
Summary
A Phase II Study of Hypofractionated Stereotactic Radiotherapy (HSRT) With Anlotinib in
Patients With Recurrent High-Grade Glioma. The primary endpoint is overall survival after
radiotherapy. Secondary endpoints included progress-free survival, objective response rate,
cognitive function, quality of life, toxicity.